CB 2 cannabinoid receptor agonists hold promise as a new class of therapeutics for indications as diverse as pain, neuroinflammation, immune suppression and osteoporosis. These potential indications are supported by strong preliminary data from multiple investigators using diverse preclinical models. However, clinical trials for CB 2 agonists, when they have been reported have generally been disappointing. This review considers possible explanations for the mismatch between promising preclinical data and disappointing clinical data. We propose that a more careful consideration of CB 2 receptor pharmacology may help move CB 2 agonists from "promising" to "effective" therapeutics.
Introduction
Cannabis derivatives have a long and storied history of medicinal use. This use has been put on a firmer scientific footing with the identification of many cannabis constituents (cannabinoids) and the elucidation of an endogenous cannabinoid signaling system. This latter system is comprised of cannabinoid receptors, the endogenous cannabinoids (endocannabinoids) that engage those receptors, and the enzymes that synthesize and degrade endocannabinoids (Howlett et al., 2002) . The long history of medicinal cannabis use, plus the richness of the endogenous cannabinoid signaling system offers many opportunities for the therapeutic applications of cannabinoids and drugs that modulate the endocannabinoid system. Unfortunately, many of these opportunities have not been realized. This review will focus on why this may be the case for CB 2 cannabinoid receptors.
The primary receptors of the endocannabinoid system are the CB 1 and CB 2 cannabinoid receptors. Of these, the CB 1 receptor is the best studied. These receptors mediate the psychoactivity of cannabis, as well as the antiemetic and analgesic actions of Δ 
